Drug Trial Radar · NCT04044001
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Nov 15, 2019
Primary completion
Mar 3, 2022
Study completion May 31, 2022
Sponsor
- Lead sponsor
- Michael HoelscherAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European and Developing Countries Clinical Trials Partnership (EDCTP); Radboud University Medical Center; German Federal Ministry of Education and Research
- First posted
- Aug 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once daily over 14 days to participants with newly diagnosed, uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis. The primary objective is to assess the safety and tolerability of BTZ-043 given over 14 days by evaluation of adverse events during treatment and follow-up period in patients with newly diagnosed, uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis.
Conditions
- Pulmonary Tuberculoses
- Other Specified Pulmonary Tuberculosis
Interventions
BTZ-043Drug
BTZ-043 (250mg per tablet)
Rifafour e-275®Drug
Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)
Probe Drug CocktailDrug
A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of * Caffeine: 1 tablet à 150mg * Tolbutamide: 1/4 tablet à 500mg * Dextromethorphan: 10 ml syrup à 15mg/5ml * Midazolam:2 ml solution à 5mg/5ml * Digoxin: 2 tablets à 0.25mg
Dolutegravir 50mg TabDrug
1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of BTZ-043Time frame: Day 1 to Day 22
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
TASK Applied Sciences Clinical Research Centre
Cape Town, South Africa
University of Cape Town Lung Institute (UCTLI)
Cape Town, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.